Operator
Good morning, ladies and gentlemen, and welcome to the Baxter International Second Quarter 2021 in Conference Call. [Operator Instructions]
I would now like to turn the call over to Ms. Clare Trachtman, Vice President of Investor Relations at Baxter International. Ms. Trachtman, you may begin.
Clare Trachtman
Vice President of Investor Relations
Good morning, and welcome to our second quarter 2021 earnings conference call. Joining me today are Joe Almeida, Baxter s Chairman and Chief Executive Officer; and Jay Saccaro, Baxter s Chief Financial Officer. On the call this morning, we will be discussing Baxter s second quarter 2021 financial results and full year 2021 financial Outlook. With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook for the third quarter and full year 2021, new product development, business development and regulatory matters contain forward-looking statements t
Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the global launch of PrisMax 2, the latest version of the company’s next-generation platform. PrisMax 2 is designed to help simplify delivery of continuous renal replacement therapy (CRRT) and other organ support therapies, while .
(0)
System further enhances user experience and helps address the evolving challenges of the intensive care unit
TrueVue digital health solutions simplify connectivity with critical hospital data systems and offer actionable insights to support CRRT quality improvement programs
PrisMax 2 system enables ECCO
2R therapy with
PrismaLung+ blood-gas exchanger, currently available in select markets in western Europe
Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the global launch of
PrisMax
2, the latest version of the company s next-generation platform.
PrisMax 2 is designed to help simplify delivery of continuous renal replacement therapy (CRRT) and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU). The
Search jobs 22-Apr-2021 Baxter Receives Grant From German Federal Ministry of Education and Research to Lead Extracorporeal Blood Purification Research
Focused on enabling more selective approaches for certain extracorporeal blood purification (EBP) therapies
Led by Baxter’s renowned research and development team in Hechingen, Germany
Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced it received a new research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF). With the grant, Baxter will lead an initiative aiming to create a new technology platform enhancing the ability to target selective removal of pathogenic substances during certain extracorporeal (outside the body) blood purification (EBP) therapies. The grant provides €1.5 million in funding over three years to Baxter and its research partners through the BMBF’s “Biomaterials Platform: Mat2M